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With a worldwide prevalence of about 1 in 3500–5000 individuals, Retinitis Pigmentosa (RP) is the most
common form of hereditary retinal degeneration. It is an extremely heterogeneous group of genetically
determined retinal diseases leading to progressive loss of vision due to impairment of rod and cone pho-
toreceptors. RP can be inherited as an autosomal-recessive, autosomal-dominant, or X-linked trait. Non-
Mendelian inheritance patterns such as digenic, maternal (mitochondrial) or compound heterozygosity
have also been reported. To date, more than 65 genes have been implicated in syndromic and non-
syndromic forms of RP, which account for only about 60% of all RP cases. Due to this high heterogeneity
and diversity of inheritance patterns, the molecular diagnosis of syndromic and non-syndromic RP is very
challenging, and the heritability of 40% of total RP cases worldwide remains unknown. However new
sequencing methodologies, boosted by the human genome project, have contributed to exponential
plummeting in sequencing costs, thereby making it feasible to include molecular testing for RP patients
in routine clinical practice within the coming years. Here, we summarize the most widely used state-of-
the-art technologies currently applied for the molecular diagnosis of RP, and address their strengths and
weaknesses for the molecular diagnosis of such a complex genetic disease.
 2012 Elsevier Ltd. All rights reserved.1. Introduction
The term Retinitis Pigmentosa (RP) encompasses a broad group
of genetically determined retinal diseases caused by a large num-
ber of mutations that result in rod photoreceptor cell death fol-
lowed by gradual death of cone cells, eventually leading to
blindness. Thus, typical RP is also described as a rod-cone dystro-
phy, in which loss of rod function exceeds the reduction in cone
sensitivity (Hamel, 2006; Hartong, Berson, & Dryja, 2006). RP is
the most common form of hereditary retinal degeneration with a
worldwide prevalence of about 1 in 3500–5000, with a total
of more than 1 million affected individuals (Chang et al., 2011;
Chizzolini et al., 2011; Collin et al., 2010). Affected individuals ﬁrst
experience defective dark adaptation (night blindness), followed
by reduction of the peripheral visual ﬁeld (known as tunnel vision)
and sometimes, loss of central vision late in the course of the dis-
ease. In the progression of RP symptoms, night blindness generally
precedes tunnel vision by years or even decades. At the cellular
level, the retinal pigment epithelium is altered in most cases,
presenting clusters of pigment within the retina of RP patients;ll rights reserved.
stia, Paseo Dr. Begiristain s/n,
00 62 50.
derra).hence the name to the disease. The onset, progression and severity
of the disease is genetically determined in most cases and also
inﬂuenced by the mode of inheritance. In extreme cases, patients
may present a rapid evolution over two decades, but in contrast,
other patients exhibit slow progression, which may never lead to
blindness (Hamel, 2006). Nevertheless, symptoms typically start
in the early teenage years and severe visual impairment occurs
by ages 40–50 years (Sahni et al., 2011).
RP can be divided into two groups: non-syndromic RP in which
RP is restricted to the eyes, without other systemic manifestations
and syndromic RP in which patients present associated non-ocular
diseases, the latter representing 20–30% of total cases (Chang et al.,
2011; Ferrari et al., 2011). Themost common forms of syndromic RP
are: Usher’s syndrome, which is characterized by RP and sensory-
neural hearing impairment, with or without vestibular dysfunction
(Williams, 2008) and the Bardet–Biedl syndrome, which is charac-
terized by RP with obesity, polydactyly, mental retardation, hypo-
gonadism and renal failure in some cases (Beales et al., 1999). The
Bardet–Biedl syndrome is due to mutations in at least 11 genes,
with cases of triallelic and digenic inheritance (Hamel, 2006). On
the basis of its inheritance pattern and prevalence, RP can be di-
vided into three main groups: autosomal-dominant (30–40% of
cases), autosomal-recessive (50–60%) and X-linked (5–15%). Pa-
tients with no other affected relatives are typically autosomal
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tions, instances of uniparental isodisomy or, for males, X-linked
mutations, or even non-Mendelian inheritance patterns, such as
digenic inheritance, compound heterozygosity or maternal (mito-
chondrial) inheritance (Audo, Bujakowska, et al., 2011; Audo,
Lancelot, et al., 2011; den Hollander et al., 2007; Hartong, Berson,
& Dryja, 2006).
Most cases of RP are monogenic. More than 65 associated genes
have been identiﬁed, 43 of which correspond to non-syndromic RP
as of May 2012 (http://www.sph.uth.tmc.edu/retnet/). Most genes
for RP cause only a small proportion of cases, with the exception of
the rhodopsin (RHO), the USH2A and the RPGR genes which to-
gether cause 30% of all cases of RP (Daiger, Bowne, & Sullivan,
2007; Hamel, 2006; Hartong, Berson, & Dryja, 2006; Musarella &
Macdonald, 2011; Pomares et al., 2010; Sergouniotis et al., 2011;
Waseem et al., 2007). However, these genes account for only about
60% of all RP patients, while heritability in about 40% of RP patients
remains unknown (Daiger, Bowne, & Sullivan, 2007; Ferrari et al.,
2011; Sahni et al., 2011). For an update on genetic and genomic
information regarding complex genetic retinal disorders, several
databases are available, including: http://www.ensembl.org;
http://www.ncbi.nlm.nih.gov; http://www.ncbi.nlm.nih.gov/gene;
http://www.ncbi.nlm.nih.gov/homologene; http://www.sph.uth.tmc.
edu/retnet/; http://genome.ucsc.edu.
Despite the fact that many technically diverse approaches are
being investigated for the treatment of RP, there is currently no
standardized and efﬁcient treatment for this disease. The discovery
of the molecular basis of the disease has led to the development of
several assays in animal models and more recently in human trials,
with promising results. More advanced lines of research in RP ther-
apy include: the use of neurotrophic factors (Zhang et al., 2012);
gene therapy (Allocca et al., 2011; Jacobson et al., 2012; Pang
et al., 2011); retinal transplant (MacLaren et al., 2006; West
et al., 2012) and electronic prosthesis (Barry & Dagnelie, 2012;
Zrenner et al., 2011).
Several factors have made the molecular characterization of RP
a real challenge. These include the high number of genes and vari-
ants involved, as well as non-Mendelian inheritance patterns, such
as incomplete penetrance, digenic or triallelic inheritance. To fur-
ther complicate things, two different mutations in the same gene
can generate different diseases and the same mutation in different
individuals may cause distinctly different symptoms. For instance,
although mutations in the rhodopsin gene are usually linked to
dominant RP, a few rare rhodopsin mutations can cause recessive
RP. Finally, the fraction of disease-causing mutations varies with
ethnicity and geography (Daiger, Bowne, & Sullivan, 2007; Ferrari
et al., 2011; Hamel, 2006; Stone, 2003).
Methods to determine DNA sequences were developed in the
late 1970s by Frederick Sanger and Walter Gilbert, and have revo-
lutionized the science of molecular genetics. Development of the
Chain-Termination method in 1977, and especially publication of
the ﬁrst draft of the human genome in 2001 (Lander et al., 2001;
Venter et al., 2001), have boosted the blossoming of novel technol-
ogies that deliver fast, inexpensive and accurate genome informa-
tion with unprecedented cost-effectiveness, leading to the
generation of what is known as Next Generation Sequencing
(NGS) technologies. Thanks to these new methods, the technical
challenges, time and cost involved in full or partial sequencing of
the human genome have exponentially plummeted (Bowne,
Humphries, et al., 2011; Bowne, Sullivan, et al., 2011; Ferrari
et al., 2011; Lander, 2011). For instance, the per-base cost of DNA
sequencing has dropped by 100,000-fold over the last decade and
the current generation of sequencing systems can read up to 250
billion bases in a week compared with 25,000 in 1990 and 5 mil-
lion in 2000 (Lander, 2011; Service, 2006). High cost involved in
conventional methods of genome sequencing, are responsible ofthe current lack of large-scale genome sequencing studies aimed
at disease gene discovery. However, this may soon change, consid-
ering that the cost of sequencing a genome at $1000 per individual
is near to becoming a fact (Duggal, Ibay, & Klein, 2011).
Since the discovery of the rhodopsin gene, the ﬁrst one directly
linked to RP (Dryja et al., 1990), almost 65 genes have been found
to be associated with this disease. Considering recent advances in
genomic sequencing, which are changing mutation discovery par-
adigms, it seems reasonable to assume that the genetic cause of RP
will be identiﬁed in 90–95% of cases in the near future. Identiﬁca-
tion and classiﬁcation of all RP causing mutations will contribute to
a better understanding of disease variants and will be central in or-
der to provide improved diagnosis and prognosis for each patient.
This is particularly important when children, young adults or af-
fected women planning to have family are involved (Daiger,
Bowne, & Sullivan, 2007; Ferrari et al., 2011; Hamel, 2006; Shintan-
i, Shechtman, & Gurwood, 2009).
In this review, we summarize the most widely used, state-
of-the-art technologies currently employed for the molecular
diagnosis of RP. We present their main features, advantages and
disadvantages and assess their capabilities and limitations to
accomplish an accurate molecular diagnosis of such a complex
genetic disease. These techniques are presented in two main
groups: sequencing technologies and technologies specialized in
detecting genetic variants.
2. Sequencing methods
2.1. Chain-Termination or Sanger sequencing
The Chain-Termination sequencing method or Sanger method
(Sanger, Nicklen, & Coulson, 1977) has revolutionized molecular
biology, providing the backbone technology for DNA sequencing
for almost three decades and has led to a number of monumental
accomplishments, including the analysis of the whole human gen-
ome sequence (Lander, 2011). This method is considered to be the
ﬁrst-generation technology, with latest technologies being denom-
inated as Next-Generation Sequencing systems (NGSs) (Metzker,
2010).
The Sanger method is performed in four separate reactions, in
each of which are included a DNA polymerase, speciﬁc DNA prim-
ers ﬂanking the target sequence and the four different types of
deoxynucleotides (dNTPs). The key principle of this technique is
the use of chain-terminating dideoxynucleotide triphosphates
(ddNTPs). One of the four different types of radioactively labeled
ddNTPs is added to each reaction. Instead of having an –OH group,
like dNTPs, ddNTPs have a hydrogen atom attached to the 30
carbon, which causes the termination of the elongation reaction
due to their inability to form a phosphodiester bond with the next
deoxynucleotide. Thus, DNA chain length in each reaction will
depend on how long the chain was when a ddNTP is randomly
incorporated. Once the four reactions have been completed,
high-resolution electrophoretic separation in a polyacrylamide
gel is applied for separating these chains by length with a resolu-
tion of one nucleotide (Pettersson, Lundeberg, & Ahmadian,
2009; Shendure & Ji, 2008). Finally, the gel is dried onto chroma-
tography paper and exposed to X-ray ﬁlm allowing direct reading
of the DNA sequence, where a dark band in a lane indicates a
DNA fragment that is the result of chain termination after incorpo-
ration of a ddNTP (Fig. 1A).
In the early 1990s, a methodological improvement of the Sanger
method, called Dye Termination sequencing, was introduced and
has become the mainstay in automated sequencing. The main
improvement of this technique lies in the fact that each ddNTP is
labeled with a different ﬂuorescent dye, allowing sequencing in a
single reaction, rather than in four as in the Sanger method, with
Fig. 1. Sanger and Dye Termination sequencing methods. Comparison between (A)
an autoradiograph obtained using the Sanger sequencing technique and (B) an
electropherogram obtained by capillary electrophoresis using the Dye Termination
sequencing technique.
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platforms based on Dye Termination methodology are fully auto-
mated and use capillary electrophoresis in a massively parallel
way, allowing the analysis of 384 DNA samples in a single run
which makes them faster, with implemented simplicity and cost-
effectiveness and lower error rates, comparing to initial versions
(Pettersson, Lundeberg, & Ahmadian, 2009; Shendure & Ji, 2008).
Sanger sequencing reads, including Dye Termination versions,
can reach up to 800–1000 base pairs (bp) with a per-base raw
accuracy of near 100%. This accuracy is higher than that achieved
with NGS technologies, but has a much higher cost per kb, making
this technology particularly inefﬁcient for the generation of
genome-size data sets (Table 1) (Fox, Filichkin, & Mockler, 2009;
Metzker, 2010; Shendure & Ji, 2008).
Currently, the main application of this technology is direct
sequencing or re-sequencing of ampliﬁed selected PCR products
(Shendure & Ji, 2008), allowing analysis of genes and exons at
the nucleotide level to elucidate disease-causing mutations. In fact,
the Sanger technique is still the only method considered to be the
gold standard for single read approaches in clinical sample testing
and therefore is the method of choice for concluding molecular
diagnosis (Garcia-Garcia et al., 2011; Janssen et al., 2011; McGee
et al., 2010; Rajadhyaksha et al., 2010).2.2. Reverse dye-terminator (Illumina) sequencing
The Illumina sequencing system (formerly known as Solexa)
combines the use of massively parallel clonal ampliﬁcation with
cyclic reversible dye-terminator sequencing (polymerase-based
sequencing-by-synthesis). It is able to identify tens of billions of
bases per week in a single run, producing high quality sequence
data with unprecedented levels of cost-effectiveness and through-
put (Pareek, Smoczynski, & Tretyn, 2011). This has facilitated the
sequencing of complex genomes and comprehensive characteriza-
tion of the widest range of structural variants. It is currently one of
the most widely adopted NGS platforms and recent applications of
this technology includes the diagnosis of RP (Audo et al., 2012;
Bowne, Humphries, et al., 2011; Bowne, Sullivan, et al., 2011;
Janssen et al., 2011; Tucker et al., 2011).
Using focused acoustic waves, the DNA sample is randomly
sheared into fragments of 100–300 bp in length, and complemen-
tary sequences or adapters are ligated onto both ends of each frag-
ment, increasing fragment size up to several hundred bp (Shendure
& Ji, 2008). Adaptor-ligated DNA fragments are then size separated
by electrophoresis and a band between 200 and 300 bp is excised.Both strands of each size-selected, adapter-ligated DNA fragment
are denatured and attached randomly, both forward and reverse,
to nearby primers that are already covalently connected to a unique
physical location in a solid surface called a ﬂow cell (made up of a
dense lawn of adaptor complementary sequences) (Pettersson,
Lundeberg, & Ahmadian, 2009; Shendure & Ji, 2008). Each ﬂow cell
is divided into eight separate lanes which allow independent
samples to be run simultaneously (Mardis, 2008). Thereafter,
repeated cycles of bridge PCR ampliﬁcation will generate directly
on the surface, very high density colony-like local clusters (>10
million DNA clusters per each lane of the array), containing
approximately 1000 copies of each single strand DNA fragment
(Fig. 2) (Metzker, 2010; Pettersson, Lundeberg, & Ahmadian, 2009).
Sequencing is then carried out using a proprietary cyclic revers-
ible terminator-based method. This method enables detection of
single bases as they are incorporated into growing strands with a
modiﬁed DNA polymerase and a mixture of four nucleotides in
each cycle (Shendure & Ji, 2008). Just like ddNTPs in Sanger
sequencing, a ﬂuorescently labeled 30 reversible terminator base
(RT-base) will stop ampliﬁcation reactions when it is incorporated.
At this time, after laser excitation, the emitted ﬂuorescence (each
RT-base emits a different ﬂuorescence signal) from each cluster
is captured by a sensitive CCD camera and the ﬁrst base is identi-
ﬁed (Pareek, Smoczynski, & Tretyn, 2011). Non-incorporated nucle-
otides are washed away to allow incorporation of the next base.
This is possible thanks to a cleavage enzyme that chops all the
blocking groups and extra molecules off (ﬂuorophores and non-
incorporated bases), and turns the RT-base into a normally func-
tioning nucleotide. Since all four reversible terminator-bound
dNTPs (A, C, T, G) are present as single, separate molecules during
each sequencing cycle, natural competition reduces the chance of
incorporation bias. The end result is true base-by-base sequencing.
Illumina technology, currently the most cost-effective technol-
ogy among all sequencing platforms, with the highest throughput,
is able to generate 10-fold more sequence data for approximately
the same cost per run than other NGS technologies. The use of in-
dexes allows the multiplexing of 96 samples per lane, which is a
very useful feature when complex genetic diseases such as RP
are involved, and reduces signiﬁcantly the cost per sample (Fox,
Filichkin, & Mockler, 2009; Loman et al., 2012). Its main limitation
is its relatively short read length capacity of about 100 bases. This
is probably due to dephasing and signal decay produced by incom-
plete incorporation of nucleotides, incomplete cleavage of ﬂuores-
cent labels or insufﬁcient removal of reverse terminators. Longer
reads are possible but at higher error rates. Thus, average raw error
rates are of the order of 0.75% per base for the Illumina GAIIx plat-
form and 0.25% for the Illumina HiSeq 2000 platform, both of
which use a paired end sequencing approach (Minoche, Dohm, &
Himmelbauer, 2011; Quail et al., 2012). The dominant error type
using Illumina technology is substitution, rather than insertions
or deletions, but homopolymers are certainly less of an issue than
with other technologies (Elliott et al., 2012; Shendure & Ji, 2008).
Another alternative, such as ABI SOLiD sequencing technology, se-
quences each nucleotide twice rather than as single bases because
it adds bases in pairs through a ligation-based sequencing tech-
nique. Thus, while Illumina will read ‘‘TAG’’ as ‘‘T’’, then ‘‘A’’, then
‘‘G’’, ABI SOLiD reads it as ‘‘TA’’, ‘‘AG’’ (Koboldt et al., 2012). This
procedure produces a double sequencing of each base and conse-
quently signiﬁcantly reduces reading error rates to about 0.15%
per base.
Illumina technology can sequence 40,000,000 templates simul-
taneously with a raw accuracy of >98% and a throughput of 600 Gb
per run thanks to the paired-end reads approach, which consists of
a simple modiﬁcation to the standard single-read DNA library
preparation. This facilitates reading both forward and reverse tem-
plate strands of each cluster during one read, allowing alignment of
Fig. 2. Schematic representation of the bridge PCR ampliﬁcation process used in the Illumina sequencing platform. (A) DNA construct with adaptors in yellow and green, and
sequence of interest in blue. (B) A dense lawn of adaptor complementary sequences (primers) covers the surface of a ﬂow cell. (C) DNA constructs bind randomly to the
primers attached to the ﬂow cell. (D and E) DNA elongates along the bound DNA template. (F) The de novo synthesized sequence dissociates from the template strand. (G) The
de novo synthesized sequence binds to an adjacent primer, generating a bridge, and the template strand is removed (arrow). (H) Bridge ampliﬁcation takes place. (I) Both
strands dissociate. (J) Non-attached extremes bind to new primers and a new bridge ampliﬁcation cycle starts (modiﬁed from Illumina.com).
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platform over other sequencing platforms, such as pyrosequencing
(Roche/454 GS FLX) or sequencing by oligonucleotide ligation and
detection (ABI SOLiD), is also due to its lower consumable cost per
Gb, which is approximately 1% of the cost of Sanger sequencing
(Pareek, Smoczynski, & Tretyn, 2011; Pettersson, Lundeberg, &
Ahmadian, 2009).
2.3. Ion Semiconductor (Ion Torrent) sequencing
Ion Torrent Semiconductor sequencing also known as pH-med-
iated sequencing or silicon sequencing is a rapid (4.5 h per run for
1 Gb output), simple, massively scalable and economical sequenc-
ing system. Ion Torrent, rather than relying on optical or imaging
technology, measures variations in pH induced by the release of
a positively charged hydrogen ion, coupled to nucleotide incorpo-
ration, a process coined as ‘‘sequencing by synthesis’’ (Glenn,
2011; Rothberg et al., 2011). Thus, semiconductor sequencing obvi-
ates the need for optical methods, electromagnetic intermediates,
specialized nucleotides or other technical challenges required in
previous sequencing techniques (Glenn, 2011; Pareek, Smoczynski,
& Tretyn, 2011; Rothberg et al., 2011; Sanger, Nicklen, & Coulson,
1977).
The Ion Torrent device uses a high-density array of nano-scale
wells to sequence in a massively parallel way. These nano-wells,each holding a different DNA fragment, are on top of a complemen-
tary metal–oxide semiconductor chip (CMOS), beneath which is an
ion sensitive layer, a pH meter, below which is a proprietary Ion
Sensitive Field Effect Transistor Sensor (ISFET) which transmits
electrical current (Pareek, Smoczynski, & Tretyn, 2011; Rothberg
et al., 2011). To sequence the template, the DNA to be deciphered
is ﬁrst fragmented. Obtained fragments are then attached to adapt-
ers, ampliﬁed by emulsion PCR and linked to a nano-well on the
chip (Rothberg et al., 2011). The device is ﬂooded along with each
of the four different unmodiﬁed bases (dNTPs), one type of base at
a time. When a dNTP complementary to the next nucleotide of the
fragment is incorporated, pyrophosphate is released and a posi-
tively charged hydrogen ion is generated. The charge from the
ion changes the pH of the solution, which is detected by the ISFET
ion sensor leading to a shift in voltage that is ultimately translated
into readout of the DNA being sequenced without scanning, cam-
eras or light mediation. If added dNTP in this cycle are not comple-
mentary, no incorporation and no biochemical reaction occurs.
Unattached dNTP molecules are washed out and another cycle be-
gins with a different type of base. When the ion sensor is excited,
electrical pulses are transmitted by the chip and the software dis-
plays the produced data as an ionogram and the sequence can be
read from it with no intermediate signal conversion (Fig. 3).
The presence of a homopolymer stretch on the sequenced DNA
causes incorporation of multiple dNTPs, with the corresponding
Fig. 3. Ion Torrent. An ionogram corresponding to the ﬁrst 55 ﬂows from one well.
The Y-axis indicates the number of base pairs incorporated per well. The X-axis
indicates the ﬂow number, with corresponding DNA base pairs. Note that colors are
assigned to bases in order to follow the Sanger sequencing nomenclature, since Ion
Torrent technology is based on pH variation, with no ﬂuorescence involved
(unpublished results).
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tional increase in pH and therefore in the electronic signal. How-
ever signals from those repeats with a 1 base difference are
difﬁcult to discriminate. This limitation in accuracy of sequencing
highly repetitive regions is shared by other techniques that detect
single nucleotide additions, such as pyrosequencing (Elliott et al.,
2012; Loman et al., 2012), and should be taken into consideration,
since these regions can be important contributors to heritable dis-
eases (Gonzalez et al., 2007; Pareek, Smoczynski, & Tretyn, 2011).
The initial scope of this technology was small scale, quick-turn-
around jobs like de novo bacterial artiﬁcial chromosomes (BACs),
plasmids and microbial genome sequencing, microRNA sequencing
or targeted re-sequencing, and was limited by the impossibility of
making long length reads (Glenn, 2011; Pareek, Smoczynski, &
Tretyn, 2011). The recent launch of the Personal Genome Machine
(PGM) and Ion Proton sequencers with enhanced chip density (314,
316 or 318 chips) have improved read length from 100 bp to
200 bp, Mb per run yield (from 10 Mb to 1 Gb) and cost per Mb
(about 5-fold) (Glenn, 2011; Robison, 2011). These two new Ion
Torrent sequencers, although sharing semiconductor technology,
are designed for different genetic approaches: the PGM sequencer
is recommended for small-genome sequencing, sequencing sets of
genes, ChIP-Seq, and gene expression approaches, whereas the Ion
Proton sequencer is more suited to human genome sequencingTable 1
Key features of the principal Next Generation Sequencing technologies currently available
Sanger 454 Pyroseq Illumina HiSeq 2000 ABI SOL
Sequencing
method
Dideoxide
sequencing
Pyrosequencing Reversible
terminator
chemistry
Ligation
sequenc
Ampliﬁcation
approach
Multiplex PCR Emulsión PCR Bridge PCR Emulsió
Gb per run (throughput) Single s
sample
1a 21–35 100
Running time 2–3 h 7 h 8.5–11 daysa 7 daysa
Read lengths 1000 bp 400–500 bp 150  2 bpa 35  75
Costb 0.5c 84.00 0.035 0.04
a Paired-end runs.
b Estimated costs per Mb provided by manufacturers in USD.
c Indicates cost per Kb.projects, including whole genome, exome or transcriptome
sequencing (Life Technologies. Ion Proton sequencer and PGM
sequencer Data Sheets, 2012).
An advantage of ion semiconductor sequencing over many
other approaches is that a simple run can be completed within
hours, compared with previous NGS systems which have run times
ranging from days up to 2 weeks. The fast performance associated
with this technology has allowed the characterization of an Esche-
richia coli strain in the early stages of a severe pathogenic outbreak
by the rapid whole genome sequencing of this microorganism
(Mellmann et al., 2011; Robison, 2011).
Reﬁning of this technology, mainly based on PES methodology,
as described in Section 2.2, has allowed improved resolution of
insertions and deletions, reducing reading errors by about 5-fold
to 0.19% with a reported consensus accuracy of about 1 error per
1000 bases in 100 Mb. However, this accuracy and error data
regarding the human genome are exclusively provided by the de-
vice manufacturers, with the exception of a recent study for the
detection of disease-causing mutations in cystic ﬁbrosis (Elliott
et al., 2012). Using semiconductor sequencing, they reported a
false-positive call on the 2184delA in a CFTR locus in 35% of the
reads spanning this variant that lies in a homopolymer stretch of
seven adenines, which was misinterpreted as a point deletion.
For this reason, the current high rate of false positives using semi-
conductor sequencing makes this technology more suitable for
other applications rather than for full gene sequencing, such as
hotspot variant detection. Independent data regarding bacterial,
viral or non-human mammalian genome sequencing has been re-
ported by several groups (Howden et al., 2011; Mellmann et al.,
2011; Miller et al., 2011; Vogel et al., 2012).
Currently, several companies and universities are offering diag-
nostic services for RP, using NGS technology. Some examples in-
clude: The Casey Eye Institute Molecular Diagnostics Laboratory
(Portland, Oregon. USA, https://www.ohsu.edu/xd/health/ser-
vices/casey-eye/diagnostic-services/cei-diagnostics/tests-we-offer.
cfm); the Center of Genomics and Transcriptomic CeGaT (Tuebin-
gen, Germany, http://www.cegat.de/List-of-genes-(by-disease)_l=
1_41.html); the Centrum Medische Genetica (Ghent, Belgium,
http://medgen.ugent.be/CMGG/onderzoek.php?topic_id=81); the
John andMarcia Carver Nonproﬁt Genetic Testing Laboratory (Iowa
City, IOWA. USA, https://www.carverlab.org/faqs/disease-descrip-
tions/rp); GeneDx (Gaithersburg, Maryland, USA, http://www.
genedx.com/test-catalog/disorders/retinitis-pigmentosa-x-linked/);
Fundación Jimenez Diaz, http://www.fjd.es/instituto_investiga-
cion/es/investigacion/genetica/genetica_genomica.html); and As-
per BioTech (http://www.asperbio.com/asper-ophthalmics).
The main features of sequencing technologies reviewed here, as
well as other currently available NGS technologies, such as 454.
iD 4 Ion Torrent Heliscope SMRT
-based
ing
Ion semiconductor
sequencing
Single-molecule
sequencing
Single-molecule
sequencing
n PCR Emulsión PCR No ampliﬁcation
(single molecule)
No ampliﬁcation
(single molecule)
equence/ 0.40–0.60 600a >100a
4.5 ha 8 days 1 h
bpa 200 bp 25–55 bp 3000–10,000 bp
0.93 0.45–0.60 Not determined
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and SMRT, also included in the Table 1, are brieﬂy described in
Section 4.3. Genetic variant detection methods
3.1. DNA microarray technology
Microarray technology, also referred to as DNA chips, is a fast
and efﬁcient high-throughput screening and validation technique
successfully used in the diagnosis of several pathologies including
glioblastoma, colorectal cancer, chronic lymphocytic leukemia, Idi-
opathic Generalized Epilepsy or autism (Dhawan et al., 2012;
Dougherty et al., 2012; Hochstenbach et al., 2011; Jasmine et al.,
2012; Leone et al., 2012; Zhang et al., 2011). For a detailed review
of its application in diagnosis see Keren and Le Caignec (2011) and
Sato-Otsubo, Sanada, and Ogawa (2012).
This technology, originally designed to detect genomic copy
number variation (CNV) and to perform Single Nucleotide Poly-
morphism (SNP) genotyping, allows for whole genome analysis
of patient samples using a chip-based format. Current improve-
ments in DNA array features have contributed to making them very
popular for clinical research purposes. Analysis of thousands to
millions of SNPs in parallel can be performed, allowing large-scale
genotyping studies with minimal hands-on processing per plate.
Applications for DNA arrays currently include clinical genetics
and diagnosis, such as: gene expression proﬁling, alternative splic-
ing detection, loss of heterozygosity testing, uniparental disomy or
DNA adenine methyltransferase identiﬁcation (Bibikova et al.,
2006; Gardina et al., 2006; Lin et al., 2004; Lindblad-Toh et al.,
2000; Tucker et al., 2012; Vardhanabhuti et al., 2006).3.1.1. SNP or polymorphism microarrays
Variation in single nucleotide polymorphisms (SNPs) and copy
number variations (CNVs) within individuals play major roles in
common human diseases. They may determine the difference
between affected and healthy individuals and are being
extensively used as genetic markers (Almal & Padh, 2012; Vissers
& Stankiewicz, 2012). SNP or polymorphism microarrays are
designed to detect most types of the SNP and CNV variants which
have been previously ascertained through several major SNP
discovery initiatives, such as NCBI dbSNP, the 1000 Genomes
Project, UCSC genome browser‘s database and the NHLBI Sequenc-
ing Project (http://www.ncbi.nlm.nih.gov/projects/SNP/; http://
www.1000genomes.org/; http://genome.ucsc.edu/ and http://www.
nhlbi.nih.gov/resources/exome.htm; Hoffmann et al., 2012; Kim &
Misra, 2007; Rocha et al., 2006; Schaaf, Wiszniewska, & Beaudet,
2011; Smith, 2008; Sung et al., 2012).
Microarrays are miniature devices made of silicon glass
(1 cm2) composed of millions of micrometer-scale beads or wells,
each holding hundreds of thousands of identical copies of short
single-stranded DNA oligonucleotides – the probe – immobilized
at a different and strategic position on the array. Probes exploit
the natural chemical attraction between DNA strands to hybridize
or to selectively anneal only to those DNA molecules with a perfect
match. Therefore such arrays can be used to identify the presence
of a particular allele in the context of a single individual’s entire
genome.
Attending to the purpose of the study, DNA arrays can be di-
vided in two main groups: those arrays used for the molecular
diagnosis of speciﬁc genetic disorders, which typically require
identiﬁcation of hundreds to a few thousands of SNPs in parallel
(Krjutskov et al., 2008; LaFramboise, 2009; Nevelin et al., 2012;
Piñeiro-Gallego et al., 2011) and another group of arrays capable
of performing parallel analysis of millions of SNPs, commonly usedfor genome-wide association study (GWAS), which are efﬁcient to
locate genes or loci that may harbor disease alleles (Duggal, Ibay, &
Klein, 2011; Hoffmann et al., 2012; Hunter et al., 2007; Levine
et al., 2012; Rodenburg et al., 2012).
Among the molecular diagnosis-oriented arrays, Arrayed Primer
Extension or APEX microarray technology, combines hybridization
and four-color single-base primer extension reactions. This tech-
nology can genotype hundreds to thousands of genetic variations
in parallel, including single base substitutions, deletions and inser-
tions (Krjutskov et al., 2008; Pereiro et al., 2011; Pullat & Metspalu,
2008; Shumaker, Metspalu, & Caskey, 1996).
The APEX reaction consists of a three-step reaction mechanism:
(1) ampliﬁcation of targeted DNAwhich harbors mutations or SNPs
of interest; (2) hybridization between targeted DNA and primers
attached to the beads (acting like probes) designed to hybridize
immediately adjacent to the loci of interest, stopping one base be-
fore the interrogated marker; and (3) single base enzymatic exten-
sion using a thermostable DNA polymerase together with four
different terminator nucleotides each tagged with a different ﬂuo-
rophore. The newly incorporated nucleotide terminates the exten-
sion reaction and represents the base of interest. Then, four lasers
(one at a time) are used to excite the different dyes and the light
emitted is uses to interrogate the nature of the nucleotide in the
position of interest (Pullat et al., 2008). It requires about 2.5–
6 lg of genomic DNA and 2 days to perform the assay.
APEX microarrays for the diagnosis of non-syndromic and syn-
dromic RP are commercially available. Non-syndromic RP variants
which can be diagnosed include adRP (covering 414 variants in 16
genes), arRP (594 variants in 19 genes) and X-linked RP (184 muta-
tions in 2 genes). Syndromic RP, such as Bardet–Biedl syndrome
(over 300 variants in 13 genes), or Usher syndrome (612 mutations
in 9 genes) can also be identiﬁed (Audo, Bujakowska, et al., 2011;
Audo, Lancelot, et al., 2011; Audo et al., 2012; Avila-Fernandez
et al., 2010; Dev Borman et al., 2012; Jaijo et al., 2010; Kimberling
et al., 2010; Mackay et al., 2011; Vozzi et al., 2011; Yzer et al.,
2006). For an updated list of DNA arrays available see (http://
www.asperbio.com/asper-ophthalmics).
There are currently two main manufacturers of GWAS-oriented
arrays. Both of these work on the same biochemical principal of
base-paring, but with some differences: Illumina arrays determine
SNP genotypes by the single-base extension technique, whereas
Affymetrix arrays use single or multiple base mismatch hybridiza-
tion technology (LaFramboise, 2009; Perkel, 2008; Schaaf,
Wiszniewska, & Beaudet, 2011).
In Affymetrix SNP arrays, probes of about 25 nucleotides long,
representing all possible alleles at a polymorphic site (typically a
pair), are attached to the 8 lm array beads. Once isolated, ampli-
ﬁed, fragmented and ﬂuorescently labeled, the DNA target se-
quence is applied to the chip, which will hybridize only to
those probes which are perfectly complementary. The array is
scanned and the intensity of ﬂuorescent signals is measured to
quantify the relative amount of sample bound to each bead. The
position of ﬂuorescent signals within the array will identify which
alleles are present in that particular genome sample. Affymetrix ar-
rays are capable of determining in a single assay up to 1.8 million
common and rare validated genetic variants, including insertion/
deletions, which typically require 500 ng of genomic DNA and
3–4 days, for an average SNP reported call rate of >99% and an
average sample repeatability of >99.8% (Affymetrix Genome-Wide
Human SNP Array 6.0. data sheet). This technology has been cho-
sen for genotyping in projects related to retinal disorders (Bowne,
Humphries, et al., 2011; Bowne, Sullivan, et al., 2011; Gonzalez-del
Pozo et al., 2011; Ostergaard et al., 2011; Roesch, Stadler, & Cepko,
2012).
On the other hand, the Ilumina SNP array uses the single-base
extension technique and a dual color channel approach to identify
A. Anasagasti et al. / Vision Research 75 (2012) 117–129 123and score up to 4.3 million markers per single DNA sample. Unlike
the Affymetrix assay, which utilizes one probe type per all possible
alleles in a locus, the Illumina chip only uses a single probe – of
about 50 bases – per locus. In this case, the probe is designed to
hybridize immediately adjacent to the locus of interest, stopping
one base before the interrogated marker, thereby not containing
the SNP itself. By using this approach, there is no need to design
a different probe for each SNP in each locus, thereby increasing
the capacity of SNP genotyping (Schaaf, Wiszniewska, & Beaudet,
2011).
In Illumina SNP arrays, DNA target hybridizes to a locus-speciﬁc
bead. Then, SNP locus-speciﬁc primers are extended in the pres-
ence of labeled dideoxynucleotides (biotin-labeled ddCTP and
ddGTP, and dinitrophenyl group-labeled ddATP and ddUTP). These
dideoxynucleotides are efﬁciently incorporated by polymerases
and detected in a dual-color assay. Bead ﬂuorescence is analyzed
using Illumina software for automated genotype calling, based on
color and signal intensity (Steemers et al., 2006). With respect to
sample requirements, 750 ng of DNA is sufﬁcient to process over
500,000 SNP loci in 3 days, with an average SNP reported call rate
and reproducibility of about 100% (Illumina HumanOmni5-Quad
BeadChip data Sheet). Recent studies were based on Illumina Bead-
Chips to perform genome-wide homozygosity screening for arRP
and X-linked RP families (Kannabiran et al., 2012; Siemiatkowska
et al., 2011).
The main drawback of microarray-based genotyping, is that it is
only valid for known genetic variants, excluding newly discovered
SNPs. Both Illumina and Affymetrix are now producing arrays with
two components: one determined and another customizable, in
which researchers can incorporate a limited number of last minute
discovered SNPs. This allows researchers to tailor the SNP chip to
their needs, although at a signiﬁcantly higher chip cost.
Taqman OpenArrays (Applied Biosystems) offer a fully custom-
izable array platform, which allows researchers to design custom
arrays to detect any new SNP. This technology uses the 50 exonu-
clease activity of the Taq polymerase, together with two Taqman
probes to discriminate between the two alleles of an SNP. Taqman
probes consist of two oligonucleotides, each complementary to one
of the two alleles of the SNP, with a ﬂuorophore cova-
lently attached to the 50-end and a quencher at the 30-end. Quench-
er molecules suppress the ﬂuorescence emitted by the ﬂuorophore
when excited by the cycler’s light, as long as the ﬂuorophore and
the quencher are close enough. During the annealing-extension
step, the probe hybridizes to the amplicon and polymerase breaks
the union between the quencher and the DNA, resulting in an in-
crease of ﬂuorescence due to physical separation of the quencher
from the ﬂuorophore. The emitted ﬂuorescence is directly propor-
tional to the amount of DNA and indicates the type of alleles that
are present in the sample. The Taqman OpenArray platform con-
tains 3072 microscopic through-holes grouped in 48 subarrays of
64 through-holes each, enabling the parallel genotyping of up to
256 different SNPs per array. Running time for this assay is about
8 h from puriﬁed DNA to genotyping results and 125 ng of DNA
is required per sample (Hopp et al., 2010; Pomeroy et al., 2009;
Roberts et al., 2009).
More recently, a fully customizable platform has become avail-
able; the qBiomarker PCR array (SABioscience; Qiagen) allows the
complete design of an array with the SNPs chosen by the research-
er (patent pending).
3.2. High Resolution Melting (HRM) analysis
HighResolutionMelting (HRM) analysis is a fast and cost-effective
post-PCR analysis method that provides a rapid identiﬁcation
of genetic variation, based on biophysical measurement of the
ampliﬁed DNA (Aguirre-Lamban et al., 2010; Carrillo et al., 2012;Dufresne et al., 2006; Sergouniotis et al., 2011; Smith, Lu, &
Alvarado Bremer, 2010; Vossen et al., 2009). Transition of the
double-stranded DNA molecule to its two single strands – DNA
denaturation or melting – allows the study of DNA structure and
composition by measuring the change of ﬂuorescence intensity
per unit of time. HRM gives valuable information for mutation
screening, genotyping, methylation, microsatellite analysis and
other research applications (Arthofer, Steiner, & Schlick-Steiner,
2011; Mader, Lukas, & Novak, 2008).
HRM is faster (1.5–3 h), simpler and less expensive than other
DNA variation analysis techniques, due to the lack of addition, pro-
cessing or separation steps involved (Erali & Wittwer, 2010). Reac-
tion and analysis take place in the same instrument (closed-tube
method) minimizing manipulation errors (Reed, Kent, & Wittwer,
2007). These facts contribute to making HRM analysis more sensi-
tive and speciﬁc than other techniques, such as denaturing high
performance liquid chromatography (dHPLC), single-strand con-
formation polymorphism (SSCP) and restriction fragment length
polymorphism (RFLP) (Aguirre-Lamban et al., 2010; Joly et al.,
2011). Recent availability of advanced double-stranded DNA
(dsDNA)–binding dyes, along with next-generation real-time PCR
instrumentation and analysis software have increased its sensitiv-
ity and accuracy and have improved the clinical potential of this
technology.
HRM analysis starts with targeted PCR ampliﬁcation in the pres-
ence of a dsDNA-binding dye. Mutations can be detected at any
location in the amplicon, including those located right after the pri-
mer sequences. As the PCR product gradually dissociates into sin-
gle strands, dye is released with a strong loss of ﬂuorescence
emission related to the process (1000-fold decrease). Emitted
ﬂuorescence is measured with specialized instrumentation which
generates a precise characteristic curve from a large number of
ﬂuorescent data points per change in temperature. By measuring
the melting temperature (Tm: when 50% of the DNA is double-
stranded), amplicons that differ by only a single base compared
with reference wild type (WT) samples can be resolved (Dufresne
et al., 2006; Vossen et al., 2009).
An interesting feature of HRM analysis is its power to detect
all categories of variations, including substitutions, inversions,
insertions and deletions, ranging from single to 63 bp mutations,
provided that they are small enough to be ampliﬁed by PCR,
with forward and reverse primers bracketing the variation
(Bastien et al., 2008; De Leeneer et al., 2008; Dufresne et al.,
2006; Kennerson et al., 2007; Reed, Kent, & Wittwer, 2007; van
der Stoep et al., 2009). Thus, multi-exon deletions may remain
undetected by this technique (De Leeneer et al., 2008).
The sensitivity of heterozygote detection is remarkable, with
several studies reporting detection of all heterozygous mutations
examined (Audrezet et al., 2008; Kennerson et al., 2007; Lonie
et al., 2006; Takano et al., 2008). Homozygous variants differ in
Tm from the WT samples whereas heterozygous variants produce
a remarkable modiﬁcation in curve shape, rather than in Tm. The
latter are better resolved by using melting curve advanced plots,
such as ‘‘Difference Plot’’, where small differences in melt curve
data are ampliﬁed (Liew et al., 2004).
Changes in Tm are base-speciﬁc. Class I (C/T; G/A) and II (C/A;
G/T) produce a greater change in Tm, with an average of >0.5 C,
compared with class III (C/G), with an average of 0.2–0.5 C or class
IV (A/T), with an average of <0.2 C. Thus, mutations involving class
III and IV are associated with a decreased sensitivity of homozy-
gote detection (Liew et al., 2004; Sergouniotis et al., 2011). One ap-
proach that can be used to increase the power of resolution of
single point mutations is to add WT DNA to control and unknown
samples (at a 1:6 ratio) to create artiﬁcial heterozygotes, with all
genotypes distinguished by quantitative heteroduplex analysis
(Seipp, Herrmann, & Wittwer, 2010; Wittwer, 2009). Factors other
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genomic quality, primers design, amplicon length and PCR reagent
choice, including dye selection and ionic strength (Liew et al.,
2004). Amplicon lengths ranging between 100 and 300 bp, includ-
ing primers, are generally recommended for sequence variant
detection.
Mutation discovery in human diseases has been the largest area
of HRM application, with investigations into autosomal dominant,
recessive and X-linked disorders (Cherbal et al., 2012; Kennerson
et al., 2007; Krypuy et al., 2007). To date, hundreds of mutations
in more than 60 genes have been analyzed with this technology,
including genes associated with RP, such as C2ORF71, USH2A or
ABCA4 (Aguirre-Lamban et al., 2010; Sergouniotis et al., 2011; Xu
et al., 2011). We have recently found HRM analysis to be an appro-
priate approach as a massive genetic screening method when com-
bined with direct sequencing, being particularly suited for
relatively small (<4 kb) RP genes with medium/high prevalence,
such as USH3A, PRPF31 or ROM1 (Anasagasti et al., 2012) (Fig. 4).
3.3. Multiplex Ligation Probe Ampliﬁcation (MLPA)
The technique known as MLPA is an accurate, time-efﬁcient and
kit-based laboratory tool able to detect unusual copy number
changes in genomic sequences, with high sensitivity and speciﬁcity
(Fernandez et al., 2005). This method is specialized in detecting
large genomic rearrangements, i.e., deletions and duplications,
including entire gene exons that frequently escape conventional
and novel laboratory detection methods, including NGS (Schouten
et al., 2002). Therefore, the MLPA technique has been frequently
used in molecular diagnosis of patients with genetic disorders
caused by deletions or duplications in speciﬁc genes, such as Duch-
enne Muscular Dystrophy (DMD), Charcot–Marie–Tooth disease or
mental retardation (Dastur et al., 2011; Madrigal et al., 2007;
Marzese et al., 2008). Deletions and duplications represent about
5% of all disease-causing mutations, and recent data show that this
might be of relevance in some cases of RP (Daiger, Bowne, &
Sullivan, 2007; Roux et al., 2011; Sullivan et al., 2006). AnotherFig. 4. High Resolution Melting (HRM) analysis. (A) HRM Difference Plot analysis, corres
clearly from control samples, suggesting the presence of a genetic variant. (B) Electropher
in (A), conﬁrming the presence of a heterozygote point deletion (arrow) within exon 3
corresponding to the mutated strand that generates a shift in the reading frame (Anasaapplication of this genomic DNA technology includes SNP detec-
tion, aneuploidy determination and DNA methylation analysis, as
well as RNA based applications such as RT-MLPA and mRNA proﬁl-
ing (Diego-Alvarez et al., 2007; Slater et al., 2003).
MLPA is a multiplex PCR-based screening method designed to
determine in a single reaction tube the copy number of up to 50
DNA or RNA sequences, up to 96 samples in parallel in 24 h (Chung
et al., 2012; Stuppia et al., 2012; Vorstman et al., 2006). Unlike
standard multiplex PCR, where ampliﬁcation using unique primer
pairs for each fragment is required, MLPA reaction is performed
with only a single primer pair for all its probes, avoiding dimeriza-
tion or false priming issues. The principle of MLPA is based on the
identiﬁcation of target sequences by hybridization of two oligonu-
cleotides (ﬂuorescently labeled MLPA probes) that can be joined to
each other by a ligation reaction, only when hybridized to the tar-
get sequence. Each oligonucleotide has a PCR primer attached to
facilitate posterior identiﬁcation (Vorstman et al., 2006). Once
joined, MLPA sequences will then be exponentially ampliﬁed dur-
ing PCR, providing a unique mixture of fragments ranging between
65 and 500 bp in length, which can be identiﬁed and quantiﬁed by
capillary electrophoresis and analyzed using an automatic sequen-
cer. This allows estimating the amount of product obtained by
emission of a signal peak that can be visualized as an electrophero-
gram (Fernandez et al., 2005). Comparison of the peak probe pat-
tern emitted by the target sample with that emitted by a control
sample enables the detection of abnormal probe signals that indi-
cate variations in copy number, indicating either deletion or dupli-
cation of genomic regions of interest (Vorstman et al., 2006). A
calculated ratio from this comparison that falls outside the range
of 0.85–1.35 would indicate deletions or duplications of the sample
sequence involved.
Zygosity can also be determined by ratio comparison, since both
homozygous deletions and duplications will produce greater ge-
netic change and therefore greater change in ratios with respect
to the control sample than heterozygous deletions and duplica-
tions. Interpretation of data can be done using MLPA speciﬁc soft-
ware (Vorstman et al., 2006). An important application of thisponding to exon 3 of the ROM1 gene. Two samples (in red, each in triplicate) differ
ogram obtained by direct sequencing corresponding to one of the hit samples shown
of ROM1. Point deletion is identiﬁed by the irruption of a new ﬂuorescence signal
gasti et al., 2012).
Fig. 5. Multiplex Ligation Probe Ampliﬁcation (MLPA). Electropherogram corre-
sponding to a region of the USH2A gene of an RP patient (top) and a non-affected
individual. Arrows show 3 regions with DNA insertions, corresponding to exons 71
(left), 7 (middle) and 15 (right) (unpublished results).
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ples. If an extra gene copy is present in the target sample, a 1.5-fold
increase in emitted signal is predicted to occur, depending on the
zygosity of insertion. In contrast, if a gene copy in the target sample
is missed, the emitted signal is expected to be 0.5 times the inten-
sity of the control probes in heterozygosis, with a complete lack of
signal in homozygosis.
Currently, MLPA kits containing all the necessary reagents to
perform diagnostic screening for many genetic disorders such as
Duchenne Muscular Dystrophy (DMD) (Dastur et al., 2011; Laing
et al., 2011), Becker Muscular Dystrophy (BMD) (Lee et al., 2012;Table 2
Comparative summary of advantages and limitations of the main technologies for the det
Advantages
Sanger Gold standard for single reads
Higher accuracy (99.999%) than NGS technologies
Long reads of1000 bp
Illumina Highest throughput and most cost-effective technology among current
sequencing platforms
Higher accuracy in homopolymer detection than other platforms
Ion Torrent Easy to use, fast and low-cost instrument
No ﬂuorescent procedures/detection systems needed
Generates less noise data than other NGS platforms
Microarray Detects all types of genetic variations, including large size deletions and
duplications
Identiﬁcation of millions of SNPs in parallel
Perform GWAS analysis with high accuracy
HRM Highly cost-effective genetic screening technique
All variation types detected, including small and mid-sized deletions an
insertion
MLPA Unique for large DNA rearrangements detection
Easy to perform and interpret
Fast (results in <24 h)Lehmann-Horn et al., 2011), Marfan Syndrome (Faivre et al.,
2010; Furtado et al., 2011), von Willebrand disease (Cabrera
et al., 2011) or Aniridia (Lim et al., 2012) are commercially avail-
able. As far as Retinitis Pigmentosa is concerned, there are several
MLPA Kits marketed for genes associated with this disease, such as
PRPF-31, PCDH15, RPGR, ABCA4, LCA or USH2A (Fig. 5) (Aller et al.,
2010; Rose et al., 2011; Roux et al., 2011). Inconveniences of MLPA
technology include the existence of only one supplier (MRC Hol-
land), and the possibility of having an SNP under the probe.
For a comparative summary of the main advantages and limita-
tions of the different technologies described in the present review,
see Table 2.4. Future directions
Nowadays, we are experiencing a quantum shift in sequencing
capacity, with benchtop devices being capable of unveiling genome
sequences at unprecedented time and cost. It seems plausible thus
to predict that molecular diagnosis for RP patients will become a
routine procedure in clinical practice over the coming years. Nev-
ertheless, due to the complexity of this eye disorder at many differ-
ent levels, a number of important issues still need to be resolved.
For instance, at least 40% of RP-related genes remain to be identi-
ﬁed, disease-causing mutations must be detected and classiﬁed,
mutation testing must become inexpensive, reliable and widely
available and, clinicians must become familiar with the molecular
procedures used in order to communicate the relevant information
to patients. In this respect, one of the limitations of NGS platforms
is the interpretation of the huge amount of data generated. A mul-
tidisciplinary network of clinicians, molecular biologists and bioin-
formaticians will have to be established, if we want to extract
relevant biological information from the terabytes of data that
many laboratories are generating already.
New NGS platforms continue to appear on the market and will
surely contribute to further changing the human genome sequenc-
ing paradigm. These include Helioscope, SMRT or Nanopore tech-
nologies. The principal advantages associated with these new
technologies, in addition to greater cost-effectiveness include: (1)
sequencing based on single molecule DNA, eliminating the need
for PCR ampliﬁcation, with a signiﬁcant simpliﬁcation of theection of genetic variants and sequencing platforms.
Limitations
Poor quality in the ﬁrst 15–40 bp, with deteriorating quality of sequencing
traces after 700–900 bp
Cost-ineffective, compared to NGS
Lower accuracy than Sanger and ABI SOLiD sequencing systems
Low accuracy rates in homopolymer stretch >5 bp repeats
Low discrimination power of similarly sized homopolymers
Restricted to known mutations
Customizable arrays are cost-ineffective
Posterior direct sequencing is required in order to determine detected genetic
variants
d Work-intensive technique
Dependent on availability of speciﬁc commercial kits
Cost-ineffective
126 A. Anasagasti et al. / Vision Research 75 (2012) 117–129process and reduction of data generated; (2) read lengths are sig-
niﬁcantly higher than with Dye Termination sequencing, reaching
up to 10,000 bp and (3) signiﬁcant increase in data produced per
time invested. Note however that this information is based on data
provided by the following manufacturers, with no independent
validation: http://www.helicosbio.com/Products/HelicosregGenet-
icAnalysisSystem/tabid/140/Default.asx-http://www.paciﬁcbio-
sciences.com/–http://www.nanoporetech.com/).
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